{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:30:00Z","timestamp":1786969800561,"version":"build-2736575974"},"reference-count":5,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007452","name":"Wu Jieping Medical Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ejca.2024.114173","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T20:26:28Z","timestamp":1718310388000},"page":"114173","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma"],"prefix":"10.1016","volume":"207","author":[{"given":"Hujian","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanli","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.114173_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114089","article-title":"High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma","volume":"204","author":"Kl\u00fcmper","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.114173_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101611","article-title":"Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial","volume":"8","author":"Ferreiro-Pant\u00edn","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.114173_bib3","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41416-019-0684-2","article-title":"Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?","volume":"122","author":"Niegisch","year":"2020","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2024.114173_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.918413","article-title":"Prognostic value of normal sodium levels in patients with metastatic renal cell carcinoma receiving tyrosine kinase inhibitors","volume":"12","author":"Roviello","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2024.114173_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1080\/14712598.2019.1651288","article-title":"Do biomarkers play a predictive role for response to novel immunotherapeutic agents in metastatic renal cell carcinoma?","volume":"19","author":"Raimondi","year":"2019","journal-title":"Expert Opin Biol Ther"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2024.115101","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924008293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:22:34Z","timestamp":1786969354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924008293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":5,"alternative-id":["S0959804924008293"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114173","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Letter re: High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.114173","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114173"}}